☰

Arthur Gutierrez-Hartmann

Affiliations: 
University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Area:
Molecular Biology, Oncology, Biochemistry
Google:
"Arthur Gutierrez-Hartmann"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Rebecca E. Schweppe grad student 2000 University of Colorado, Denver
Jason D. Prescott grad student 2004 University of Colorado, Denver
Darius M. Walker grad student 2007 University of Colorado, Denver
Joanna M. Poczobutt grad student 2009 University of Colorado, Denver
Brice V. McConnell grad student 2010 University of Colorado, Denver

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Fisher MH, Kirkpatrick GD, Stevens BM, et al. (2020) ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. Jci Insight
Kar A, Koto K, Walker D, et al. (2020) ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HRHER2 breast cancer patients. Breast Cancer Research and Treatment
Roof AK, Trudeau T, Gutierrez-Hartmann A. (2018) Pituitary somatolactotropes evade an oncogenic response to Ras. Molecular and Cellular Endocrinology
Roof AK, Jirawatnotai S, Trudeau T, et al. (2018) The balance of PI3K and ERK signaling is dysregulated in prolactinoma and modulated by dopamine. Endocrinology
Kar A, Liu B, Gutierrez-Hartmann A. (2017) ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells. Anticancer Research. 37: 6583-6591
Kar A, Gutierrez-Hartmann A. (2017) ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2(+) breast cancer patients and is critical for tumorigenesis in HER2(+) breast cancer cells. Oncotarget. 8: 69622-69640
Kar A, Gutierrez-Hartmann A. (2017) ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells. Oncotarget
Roof AK, Gutierrez-Hartmann A. (2017) Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific. Molecular and Cellular Endocrinology
Yeung TL, Leung CS, Wong KK, et al. (2017) ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget
Noetzli L, Lo RW, Lee-Sherick AB, et al. (2015) Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nature Genetics. 47: 535-8
See more...